Double Bond Pharmaceuticals

Double Bond Pharmaceutical uses its proprietary drug delivery technology, BeloGal for the development of treatments for cancer, infectious diseases and other therapeutic indications. BeloGal formulations target diseased organs and are delivered intravenously or subcutaneously.


Headquarters
Double Bond Pharmaceutical International AB
Virdings allé 32B
75 450 Uppsala
Sweden

Phone / Contact

T: +46 76 164 9917
Top

W3 Total Cache is currently running in Pro version Development mode.